Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide for duodenal mucosal protection in acute pancreatitis
ChiCTR1900026180Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rebamipide in acute pancreatitis (AP) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Histological inflammation score of duodenal mucosa, Endoscopic grading of duodenal inflammation and 1 more. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
rebamipide
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR1900026180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026180.